Serum Drug Concentrations to Optimize Switching from Adalimumab to Etanercept in Rheumatoid Arthritis

Inadequate response to adalimumab can be caused by insufficient blockade of the target tumour necrosis factor (TNF) at low serum concentrations.

Rheumatoid Arthritis Pathophysiology